"Monoclonal gammopathy"

1,898 resultsPro users have access to +68 Systematic Reviews

Filter Results
          • Pro
          • Pro
          • Pro
          • Pro
          • Pro
          • Pro
                    • Pro

                            Clinical Area Pro

                            Further Refinement
                            User Guide

                            User Guide

                            1
                            2023BMJ Best Practice
                            Monoclonal gammopathy of undetermined significance Skip to main contentSkip to searchAbout usHelpSubscribeAccess through your institutionLog inBMJ Best PracticeSearchSearchSelect languageMonoclonal gammopathy of undetermined significance MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:17 Apr 2023Last updated:10 May 2023SummaryMonoclonal gammopathy of undetermined significance is an asymptomatic pre-malignant disorder associated with relatively low risk (on average 0.5% to 1.0% per year) of progression to multiple myeloma or related plasma cell proliferative malignancies.No aetiological risk factors have been defined. Male sex, older age, family history of monoclonal gammopathy of undetermined significance, African ancestry, and exposure to radiation or pesticide
                            2
                            2025British Committee for Standards in Haematology
                            Trip Score
                            NarrativeNarrative based
                            EvidenceEvidence based
                            ?
                            Diagnosis and management of monoclonal gammopathy of renal significance Summary This guideline provides consensus opinion on the investigations required for people presenting with suspected monoclonal gammopathy of renal significance to both nephrology and haematology physicians. The discusses principles treating a patient MGRS recommendations supportive management haematological therapy
                            Subscribe to Trip PRO for an enhanced experience
                            • Access to millions of Full-text articles where avaliable
                            • Unlock 100,000+ extra articles with Systematic Reviews
                            • Further Filtering Options
                            • No adverts
                            • Advanced Search Ability
                            • Enhanced SmartSearch showing unlimited related articles
                            Read more about Trip PRO
                            3
                            2023British Committee for Standards in Haematology
                            Trip Score
                            NarrativeNarrative based
                            EvidenceEvidence based
                            ?
                            Investigation and management of the monoclonal gammopathy of undetermined significance This Good Practice Paper provides recommendations for the diagnosis, risk stratification and management of monoclonal gammopathy undetermined significance (MGUS). It describes recently recognised entity clinical (MGCS), recommends how it should be managed. The potential targeted population screening MGUS
                            4
                            2021College of American Pathologists
                            Trip Score
                            NarrativeNarrative based
                            EvidenceEvidence based
                            ?
                            Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies | Archives of Pathology & Laboratory Medicine Skip to Main Content Search Dropdown Menu header search search input Search input auto suggest Search User Tools Dropdown Register Sign In Toggle MenuMenu * Home * Issues * Current Issue * Available Article * Next Article * METHODS * OBJECTIVES * RESULTS * CONCLUSIONS * References Article Navigation Research Article| August 04 2021 Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies: Guideline From the College of American Pathologists in Collaboration With the American Association for Clinical Chemistry and the American Society for Clinical Pathology David F. Keren, MD
                            5
                            2025NEJM
                            VITT-like Monoclonal Gammopathy of Thrombotic Significance. Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is associated with antibodies that target platelet factor 4 (PF4) and are heparin-independent. VITT antibodies are implicated in acute, transient prothrombotic disorders that are triggered by adenoviral vector vaccines against coronavirus disease 2019 or by adenovirus antibody. The antibody clonotype profiles and binding epitopes on PF4 were different from those observed with the acute disorders occurring after vaccination or viral infection, features that reflect distinct immunopathogenesis. Treatment strategies besides anticoagulation alone are needed for the chronic disorders, referred to as VITT-like monoclonal gammopathy of thrombotic significance. (Funded
                            6
                            2024Annals of Internal Medicine
                            Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic precursor conditions to multiple myeloma and related disorders. Smoldering multiple myeloma to the Mayo Clinic risk stratification model. iStopMM (Iceland Screens, Treats or Prevents Multiple Myeloma), a prospective population-based screening study of MGUS. (ClinicalTrials.gov: NCT03327597). Icelandic population of adults aged 40 years or older. 1043 persons with IgG, IgA, light-chain, and biclonal MGUS detected by screening and an interpretable bone marrow sample. Monoclonal gammopathy
                            7
                            2024Annals of Internal Medicine
                            Association Between Autoimmune Diseases and Monoclonal Gammopathy of Undetermined Significance : An Analysis From a Population-Based Screening Study. Monoclonal gammopathy of undetermined significance (MGUS) is a precursor of multiple myeloma (MM) and related conditions. In previous registry-based, retrospective studies, autoimmune diseases have been associated with MGUS. However, these studies
                            8
                            2023Journal of Clinical Oncology
                            Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies. The existence of patients with multiple myeloma (MM) and light-chain (AL) amyloidosis who present with a monoclonal gammopathy of undetermined significance (MGUS)-like phenotype has been hypothesized, but methods to identify this subgroup
                            9
                            2025JAMA Internal Medicine
                            Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance: A Review. Nearly 5% of adults have the precursor malignant condition monoclonal gammopathy of unknown significance (MGUS). Management centers on differentiating MGUS from more serious conditions to determine additional diagnostic testing, monitoring, and potential therapy. MGUS is defined by the absence of end-organ damage or symptoms, a small amount of monoclonal immunoglobulin (M protein), and low volume of plasma cells. MGUS must be distinguished from overt malignant diseases like multiple myeloma (MM), immunoglobulin light-chain (AL) amyloidosis, and monoclonal gammopathy of clinical significance (MGCS), all of which cause organ damage or symptoms. Although testing for M proteins is often prompted by clinical
                            10
                            2025Leukemia
                            Senescence profiling of monoclonal gammopathies reveals paracrine senescence as a crucial defense against disease progression. Multiple myeloma (MM) is a plasma cell (PC) malignancy that is preceded by monoclonal gammopathy of undetermined significance (MGUS) and/or smoldering multiple myeloma (SMM). MGUS and SMM PCs exhibit the same primary oncogenic abnormalities as MM but lack the end-organ damage that defines proliferative disease, suggesting that clonal PCs in these precursor conditions could exhibit senescence or senescence-like growth arrest. Herein we identified monoclonal gammopathy patient-derived PCs that exhibit senescence features and found that senescent PCs were significantly increased in MGUS patients compared to SMM or MM. Spatial analysis of senescent PCs in stable MGUS
                            11
                            2018BMJ Best Practice
                            Assessment of monoclonal gammopathies Assessment of monoclonal gammopathies - Differential diagnosis of symptoms | BMJ Best PracticeSkip to main contentSkip to search * About us * Help * Subscribe * Access through your institution * Log inBMJ Best Practice * Help * Getting started * FAQs * Contact us * Recent updates * Specialties * Calculators * Patient leaflets * Videos * Evidence * Drugs * Recent updates * Specialties * Calculators * Patient leaflets * Videos * Evidence * DrugsBMJ Best PracticeSearchSearch * Recent updates * Specialties * Calculators * Patient leaflets * Videos * Evidence * DrugsAssessment of monoclonal gammopathies Menu Close * Overview  * Theory  * Emergencies  * Diagnosis  * Resources  * Overview * Summary * Theory * Aetiology
                            12
                            2018BMJ Best Practice
                            Monoclonal gammopathy of undetermined significance Monoclonal gammopathy of undetermined significance - Symptoms, diagnosis and treatment | BMJ Best PracticeSkip to main contentSkip to search * About us * Help * Subscribe * Access through your institution * Log inBMJ Best Practice * Help * Getting started * FAQs * Contact us * Recent updates * Specialties * Calculators * Patient 2019SummaryAsymptomatic pre-malignant disorder associated with relatively low risk (on average 0.5% to 1.0% per year) of progression to multiple myeloma or related plasma cell proliferative malignancies.No aetiological risk factors have been defined. Male sex, older age, family history of monoclonal gammopathy of undetermined significance, African ancestry, and exposure to radiation or pesticide are associated
                            13
                            2018BMJ Best Practice
                            Assessment of monoclonal gammopathies Assessment of monoclonal gammopathies - Differential diagnosis of symptoms | BMJ Best PracticeSkip to main contentSkip to search * About us * Help * Subscribe * Access through your institution * Log inBMJ Best Practice * Help * Getting started * FAQs * Contact us * Recent updates * Specialties * Calculators * Patient leaflets * Videos * Evidence * Drugs * Recent updates * Specialties * Calculators * Patient leaflets * Videos * Evidence * DrugsBMJ Best PracticeSearchSearch * Recent updates * Specialties * Calculators * Patient leaflets * Videos * Evidence * DrugsAssessment of monoclonal gammopathies Menu Close * Overview  * Theory  * Emergencies  * Diagnosis  * Resources  * Overview * Summary * Theory * Aetiology
                            14
                            The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans. Herbicide and pesticide exposure [e.g., agent orange (AO)] is associated with an increased risk of multiple myeloma (MM) due to the contaminant, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). However , it is unclear whether TCDD/AO exposure (AO exposure hereafter) increases the risk of progression of monoclonal gammopathy of undetermined significance (MGUS) to MM. We sought to evaluate the association in a nationwide study of US Veterans. A natural language processing algorithm was used to confirm MGUS and progression to MM. We included Veterans who were diagnosed with MGUS from 10/1/1999 to 12/31/2021
                            15
                            2024BMC Cancer
                            The effects of short-term, progressive exercise training on disease activity in smouldering multiple myeloma and monoclonal gammopathy of undetermined significance: a single-arm pilot study. High levels of physical activity are associated with reduced risk of the blood cancer multiple myeloma (MM). MM is preceded by the asymptomatic stages of monoclonal gammopathy of undetermined significance
                            16
                            2024Blood
                            Multi-omics analysis in IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation. Currently, the role of DNA methylation in the IgM-monoclonal gammopathy disease spectrum remains poorly understood. In the present study, a multi-omics prospective analysis was conducted integrating DNA methylation, RNA-seq and WES data in 34 subjects [23 WM, 6 IgM-MGUS, 5 normal
                            17
                            Asymptomatic Incidence of Monoclonal Gammopathy of Undetermined Significance and Preclinical Duration to Myeloma Diagnosis: A Modeling Study. Background Monoclonal gammopathy of undetermined significance (MGUS) is the premalignant condition of multiple myeloma (MM). Given a lack of population-based screening for MGUS and its asymptomatic nature, the epidemiology of MGUS remains unknown
                            18
                            2024Blood
                            Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection. Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic pre-malignant disorder. The current standard of care is not to screen for MGUS, so it is often incidentally diagnosed in the clinic. It is unknown whether the outcomes of screened versus clinically detected MGUS
                            19
                            PARP15 is a Susceptibility Locus for Clarkson Disease (Monoclonal Gammopathy-Associated Systemic Capillary Leak Syndrome). Vascular leakage is a deadly complication of severe infections, ranging from bacterial sepsis to malaria. Worldwide, septicemia is among the top 10 causes of lethality because of the shock and multiorgan dysfunction that arise from the host vascular response . In the monoclonal gammopathy-associated capillary leak syndrome (MG-CLS), even otherwise mundane infections induce recurrent septic-like episodes of profound microvascular hyperpermeability and shock. There are no defined genetic risk factors for MG-CLS or effective treatments for acute crises. We characterized predicted loss-of-function mutations in PARP15 (poly[ADP-ribose] polymerase 15), a protein of unknown
                            20
                            The Undetermined Significance of Screening for Monoclonal Gammopathy of Undetermined Significance. The identification of premalignant lesions in solid tumors such as colorectal and cervical cancer has led to the development of highly effective population-wide screening programs for these malignancies. Although precursor clinical states are not well-established for most hematologic malignancies , multiple myeloma is a notable exception. Virtually all patients with multiple myeloma first develop monoclonal gammopathy of undetermined significance (MGUS), an asymptomatic but easily detectable condition. However, broad screening for MGUS has not been adopted primarily because there is no proven intervention to delay or prevent the progression of MGUS to multiple myeloma. Furthermore, the incidence